Originalartikel 2025

  • Cunningham CE, Vizeacoumar FS, Zhang Y, Gao P, Maranda V, Both S, Wagner K, Wu Y, Zoller BGE, Rajamanickam K, Bhanumathy KK, Elhasasna H, Kyrylenko L, Hardikkumar Patel, Dahiya R, Abuhussein O, Walke P, Dong H, T Freywald, EP Munhoz, Krishnan A, Ruppin E, B Toosi, Lee JS, Datla R, Wu Y, Empting M*, Kiemer AK*, Freywald A*, Vizeacoumar FJ*. 2025. Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality. Cell Genomics 5:100876 
     
  • Kardani A, Hemmer J, Diesel B, Mashayekhi V, Schomisch A, Koch M, Fecher-Trost C, Meyer MR, Ludwig N, Rishik S, Keller A, Hoppstädter J, Fuhrmann G, Kiemer AK. 2025. Laminar flow alters EV composition in HUVECs: A study of culture medium optimization and molecular profiling of vesicle cargo. Small Methods 9:e2401841
     
  • Risch T, Hellwinkel B, Mostert D, Kany AM, Solga D, Seedorf T, Heimann D, Hoppstädter J, Kohnhäuser D, HilgersJS, Fries F, Daschner F, Brönstrup M, Kirschning A, Sieber SA, Pietschmann M, Kiemer AK, Herrmann J, Müller R. 2025. Cystobactamid off-target profiling reveals favorable safety, superoxide reduction, and SCARB1 inhibition in eukaryotes. npj Drug Discovery 2:20